We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Uni2.5
Unifiram (DM-232) Research
Mostly mechanism / observationalLimited safety
5 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Unifiram (DM-232) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 2000–2016.
Based on 5 studies
Confidence
Low
By outcome
Cognition / anti-amnesic (animal-only, unproven in humans)
Among the compounds studied, 7 (DM 232) shows outstanding potency, being active at the dose of 0.001 mg kg(-1) sc.
Manetti D, Ghelardini C, Bartolini A, Bellucci C, Dei S, Galeotti N, Gualtieri F, Romanelli MN, Scapecchi S, Teodori E. · Journal of Medicinal Chemistry (2000)
UNIFIRAM-SPECIFIC, FOUNDATIONAL: the original disclosure of DM-232 (unifiram) — a mouse passive-avoidance study identifying it as an outstandingly potent nootropic of a new diazabicyclononanone class
DM-232 was active at about 0.001 mg/kg subcutaneously in mice, with a pharmacological profile similar to piracetam but at vastly higher potency — a rodent result, NOT a human dose or human efficacy finding
Establishes the headline 'active at 0.001 mg/kg' figure that vendors quote, in its true (animal) context
DM232 (unifiram) and DM235 (sunifiram) are potent cognition-enhancers, which are four order of magnitude more potent than piracetam ... able to increase the release of acetylcholine from rat cerebral cortex, and, as far as unifiram is concerned, to increase the amplitude of fEPSP in rat hippocampal slices.
Romanelli MN, Galeotti N, Ghelardini C, Manetti D, Martini E, Gualtieri F. · CNS Drug Reviews (2006)
UNIFIRAM-SPECIFIC: a pharmacology review characterizing unifiram (DM-232) alongside its cousin sunifiram (DM-235) — the best single overview of the compound's preclinical profile
Both compounds are ~four orders of magnitude more potent than piracetam in animal models and lack appreciable binding affinity for the major classical receptors/channels
Mechanism (preclinical): unifiram increases acetylcholine release from rat cerebral cortex and increases AMPA-mediated excitatory transmission (fEPSP) in rat hippocampal slices, implicating AMPA receptors
DM 232 and DM 235 (0.1 mg/kg i.p.) were able to reverse the amnesia induced by the AMPA receptor antagonist NBQX ... DM 232 increases, in a concentration dependent manner, excitatory synaptic transmission in the rat hippocampus in vitro. These results suggest that DM 232 and DM 235 act as cognition enhancers through the activation of the AMPA-mediated neurotransmission system.
Galeotti N, Ghelardini C, Pittaluga A, Pugliese AM, Bartolini A, Manetti D, Romanelli MN, Gualtieri F. · Naunyn-Schmiedeberg's Archives of Pharmacology (2003)
UNIFIRAM-SPECIFIC mechanism study: anti-amnesic effect of DM-232 (unifiram) in mice is blocked by the AMPA antagonist NBQX, and DM-232 enhances excitatory synaptic transmission in rat hippocampus in vitro
Supports an ampakine-like, AMPA-mediated glutamatergic mechanism for unifiram's cognition-enhancing effect — the basis for the theoretical excitotoxicity/seizure concern
At effective doses, compounds did not impair motor coordination or spontaneous activity in the rodent tests used
Structure-activity relationships on two novel potent cognition enhancing drugs, unifiram (DM232, 1) and sunifiram (DM235, 2), are reported ... two compounds (13 and 14) ... are endowed with amnesing activity (the opposite of the activity of the original molecules) and are nearly equipotent to scopolamine.
Scapecchi S, Martini E, Manetti D, Ghelardini C, Martelli C, Dei S, Galeotti N, Guandalini L, Romanelli MN, Teodori E. · Bioorganic & Medicinal Chemistry (2004)
UNIFIRAM-SPECIFIC: structure-activity relationship study around unifiram (DM-232) and sunifiram, using the mouse passive-avoidance test to map how the scaffold drives cognition-enhancing activity
Shows the structure is finely tuned — small changes can flip the molecule from procognitive to amnesia-inducing, underscoring how sensitive activity is to exactly what compound is made
Relevant to grey-market risk: a mis-synthesised or impure 'research chemical' could carry very different (even opposite) activity
I casually found that on the web, there were dozens of sites offering Unifiram and Sunifiram as drugs that improve cognition in healthy individuals even if only few preclinical studies were done and their long-term toxicity was unknown.
Gualtieri F. · Journal of Enzyme Inhibition and Medicinal Chemistry (2016)
UNIFIRAM-SPECIFIC, the grey-market story: a review by one of unifiram's own discoverers describing how DM-232/DM-235 went from the lab to dozens of web vendors selling them as cognition enhancers for healthy people
Explicitly notes that only a few preclinical studies were ever done and that long-term toxicity is UNKNOWN — the honest framing of the evidence gap
Documents the grey-market reality and the absence of human safety data, not any clinical benefit